TG Therapeutics | TGTX - Debt


TG Therapeutics reported $8.98M in Debt for its fiscal quarter ending in March of 2025.



Financials
Stock Price USD
Assets USD 702.61M
Cash and Equivalent USD 278.86M
Cost of Sales USD 18.94M
Current Assets USD 663.96M
Current Liabilities USD 171.89M
Debt USD 8.98M
EBIT USD 34.84M
EBITDA USD 12.28M
Employees 338
EPS Earnings Per Share USD 0.17
Equity Capital and Reserves USD 276.43M
Gross Profit on Sales USD 122.21M
Interest Expense on Debt USD 6.72M
Loan Capital USD 245.04M
Market Capitalization USD 4.97B
Net Income USD 28.19M
Operating Expenses USD 106.31M
Operating Profit USD 34.84M
Ordinary Share Capital USD 158.03M
PE Price to Earnings USD 88.77
Pre-Tax Profit USD 30.92M
Sales Revenues USD 141.1M
Selling and Administration Expenses USD 12.04M
Stock USD 155.2M
Trade Creditors USD 134.02M
Trade Debtors USD 231.52M

Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Alaunos Therapeutics USD 0 0 Dec/2024
Amgen USD 56.2B 1.18B Jun/2025
Ardelyx USD 206.64M 55.79M Jun/2025
Arrowhead Research USD 388.24M 21.18M Mar/2025
Bayer EUR 39.39B 1.31B Mar/2025
Biogen USD 6.59B 296.8M Jun/2025
Corcept Therapeutics USD 6.6M 6.6M Jun/2025
Dynavax Technologies USD 260.51M 36.65M Mar/2025
Gilead Sciences USD 24.95B 6M Jun/2025
J&J USD 52.25B 15.62B Mar/2025
Novartis USD 31.27B 12M Mar/2025
PTC Therapeutics USD 286.01M 2.12B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Roche Holding CHF 34.44B 5.23B Jun/2024
TG Therapeutics USD 8.98M 235.45M Mar/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025